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Clinical Investigation
Introduction
The postthrombotic syndrome (PTS) is a common long-
term complication of deep vein thrombosis (DVT), with an 
incidence rate up to 40%.1,2 Patients with PTS suffer from 
leg swelling, venous claudication, or venous ulcers that 
impair the quality of life.3,4 Of note, the risk of PTS is great-
est in patients with proximal thrombosis involving the ilio-
femoral veins or the inferior vena cava (IVC).1,4,5
Conservative management of acute iliofemoral DVT with 
anticoagulation therapy and compression stockings is associ-
ated with poor venous patency rates.6–8 Thus, early revascu-
larization strategies now aim to restore venous flow, thereby 
preventing the development of PTS.6,9 Catheter-directed 
thrombolysis followed by venous stenting has emerged as a 
promising revascularization strategy, with venous patency 
rates of 70% to 90% and low complication rates.10–20
The majority of iliofemoral DVTs are caused by iliac 
vein compression. The May-Thurner syndrome is an ana-
tomical variant in a quarter of the population that results in 
compression of the left common iliac vein (CIV) against the 
fifth lumbar vertebra by the right iliac artery.21,22 Treatment 
of venous thrombosis is particularly challenging in these 
anatomically compressed large veins. Atypical iliac vein 
compression can occur in both the left and right CIVs from 
ectatic or tortuous iliac arteries, anomalies of the vertebrae 
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Purpose: To investigate the clinical outcomes of a dedicated hybrid oblique nitinol stent that has been specifically designed 
to treat common iliac vein compression. Methods: The Bern Venous Stent Registry database was interrogated to identify 
all patients who had at least 6-month follow-up after treatment with the sinus-Obliquus hybrid stent for common iliac vein 
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or sacrum, or osteosynthetic material used during spine 
surgery.
Focal external compression and the vicinity to the ilioca-
val bifurcation hamper venous stenting using conventional 
stents. An ideal venous stent for treating iliac vein compres-
sion comprises sufficient radial force at the compression 
site and flexibility to accommodate the anatomy of the 
curved iliac vein. The exact long-term rate of contralateral 
iliac vein thrombosis after conventional left iliac vein stent-
ing is unknown. In a recent study of 51 patients with left 
CIV compression, the rate of contralateral iliac vein throm-
bosis after stenting of the left CIV with conventional non-
oblique stent with its tip positioned 1.5 cm inside the IVC 
was 4% at a mean follow-up of 16 months.23
This study investigated venous patency rates and clinical 
outcomes of patients with CIV compression treated with a 
venous hybrid nitinol stent (sinus-Obliquus; Optimed, 
Ettlingen, Germany) that has a novel oblique proximal end.24
Methods
Study Design
Data were derived from the Bern Venous Stent Registry, an 
ongoing study that has been enrolling all patients who 
receive venous stents at the University Clinic of Angiology 
in Bern, Switzerland, since January 1, 2008. Indications for 
stenting of the iliofemoral veins and/or IVC are: (1) residual 
thrombosis after catheter-directed or pharmacomechanical 
thrombolysis; (2) PTS and chronic obstruction; or (3) 
chronic venous insufficiency with nonthrombotic stenosis. 
Exclusion criteria for registry enrollment are inability to 
provide informed consent, age below 18 years, or estimated 
life expectancy <3 months.
For all enrolled patients, baseline demographic informa-
tion (age, gender, weight, height, stent type, indication); 
comorbid conditions (history of major bleeding, cardiovas-
cular comorbidity, diabetes mellitus, renal impairment); 
risk factors (tobacco use, hormonal therapy, immobility); 
laboratory findings (creatinine, hemoglobin); and antico-
agulant and antiplatelet therapy were recorded. Procedure 
data included the number and type of implanted stents, 
devices for pharmacomechanical or catheter-directed 
thrombolysis, and dosage of recombinant tissue plasmino-
gen activator (r-tPA). The registry and participant consent 
form were approved by the Swiss Ethics Committee on 
research involving humans. The study is registered on the 
National Institutes of Health website (ClinicalTrials.gov; 
identifier NCT02433054).
For this analysis, the registry database was interrogated 
to identify patients who received a sinus-Obliquus stent 
after Conformité Européenne approval in December 2014 
and had at least 6-month follow-up as of June 2016. Patients 
who were pregnant, breast-feeding, or had a postpartum 
period <30 days were excluded. The search identified 24 
patients (mean age 39±18 years; 20 women) who matched 
the search criteria and were enrolled between December 
2014 and November 2015. The baseline patient characteris-
tics are given in Table 1. The indication for stent implanta-
tion was acute iliofemoral DVT in 10 patients, PTS in 10 
patients, and nonthrombotic CIV compression in 4 patients. 
Overall, 4 patients presented with a recurrent venous throm-
boembolism (VTE).
Study Device
The sinus-Obliquus stent (Figure 1) features a proximal 
closed-cell section that provides high radial force at the 
compression site; the oblique design (35°) at the proximal 
end prevents jailing of the contralateral iliac vein. The 
open-cell distal segment affords flexibility and less radial 
force to better accommodate the curved anatomy of iliac 
veins during hip flexion.
Procedures
In acute patients, DVT was objectively confirmed by duplex 
ultrasound or contrast-enhanced computed tomography. 
Treatment of DVT, for example, anticoagulation therapy 
and thrombolysis, was at the discretion of the treating phy-
sician. In general, patients with acute DVT were treated ini-
tially with intravenous unfractionated heparin, adjusted to 
target an activated partial thromboplastin time correspond-
ing to therapeutic heparin levels (equivalent to 0.3 to 0.7 U/
mL by factor Xa inhibition). Catheter-directed therapy 
included pharmacomechanical thrombolysis if the DVT 
was confined to the iliac vein or ultrasound-assisted throm-
bolysis if the DVT extended to the femoral veins.
Pharmacomechanical thrombolysis was performed in a 
single session with the AngioJet system (DVX 6-F catheter; 
Boston Scientific, Marlborough, MA, USA) and intraclot 
injection of 10 mg of r-tPA using the high-pressure 
PowerPulse technique. Ultrasound-assisted thrombolysis 
was performed with the EKOS system (EKOS Corporation, 
Bothell, WA, USA),25,26 infusing a total 20 mg r-tPA over 15 
hours, with hemodynamic monitoring in the intermediate 
care unit. Following catheter-directed therapy, vitamin K 
antagonists were started or unfractionated heparin was 
switched to direct oral anticoagulants.
Prior to stent placement, a bilateral anteroposterior veno-
gram was routinely performed via a crossover diagnostic 
catheter and the ipsilateral sheath to visualize the exact 
location of the iliac vein confluence, the distal IVC, and the 
iliac vein compression. Intravascular ultrasound was per-
formed only if the extent and location of the CIV compres-
sion could not be visualized by bilateral venography.
The stent was advanced with its tip into the distal IVC. 
Correct positioning of the stent was achieved by (1) rotating 
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the delivery system to align the 2 middle radiopaque mark-
ers and (2) by pulling back the stent system so that the lat-
eral marker on the short end of the oblique section was 
placed ~5 mm into the IVC adjacent to the iliac vein conflu-
ence (Figure 2). Deployment of the stent was performed 
using a contrast overlay from the bilateral contrast injection 
to facilitate exact stent placement without compromising 
the contralateral IVC wall and without jailing the contralat-
eral iliac vein. If the initial deployment of the closed-cell 
section was suboptimal, the stent was retrieved into the 
delivery catheter and a new deployment initiated. Additional 
stent extensions (sinus XL Flex; Optimed) were added as 
needed for long segment treatment.
Follow-up
Clinical follow-up assessments were performed at the vas-
cular outpatient clinic by vascular specialists at baseline 
and at 3, 6, and 12 months in follow-up. At each visit, signs 
and symptoms of PTS were systematically calculated using 
the Villalta score as standard procedure for all patients with 
venous stents. A score <5 points indicated no PTS. Mild 
PTS was defined between 5 to 9 points, moderate between 
10 and 14, and >15 points was considered severe PTS.2,3 
Moreover, the severity of the symptoms was assessed using 
the revised venous clinical severity score (rVCSS).3,27 An 
additional score suggested by Bozkaya et al11 was used to 
assess subjective development of symptoms by the patients 
themselves after intervention. Patients were categorized 
into the following 3 groups: clinical improvement (com-
plete or partial) and symptoms unaffected compared to 
before intervention.
Duplex sonography was performed immediately after 
stent implantation and at 3, 6, and 12 months. Each stented 
venous segment was examined for (1) the presence or 
absence of thrombotic changes (thickening of the venous 
wall, intraluminal webs, intraluminal material); (2) the 
presence of reflux (>0.5 seconds during Valsalva maneuver 
or distal compression) in nonoccluded segments below the 
groin; and (3) flow patterns in treated segments to deter-
mine if they were modulated by the cardiac cycle, spontane-
ously modulated with respiration, or modulated with deep 
inspiration. Flow velocities were recorded.
Definition of Outcomes
Primary treatment success was defined as antegrade flow 
and maximal luminal stenosis of 30% after intervention 
examined with venography and evidence of a spontaneous 
Doppler signal in the treated vein segment.10,11,13,28 Primary 
Table 1. Baseline Characteristics.a
Characteristic Overall (n=24) PTS (n=10) Acute Thrombosis (n=10) Iliac Vein Compression (n=4)
Age, y 39±18 36±12 37±23 47±18
Women 20 9 8 3
May-Thurner syndrome 20 8 9 3
Peripheral artery disease 1 0 1 0
Cerebrovascular disease 1 0 1 0
Liver insufficiencyb 1 0 1 0
Hypertension 1 0 1 0
Diabetes 3 1 2 0
Smoking 10 3 5 2
Obesity 1 1 0 0
Previous VTE 4 3 1 0
Postpartum statusc 1 1 0 0
Hormonal therapyd 7 1 5 1
Surgery and/or traumae 2 2 0 0
Immobilizationf 6 3 3 0
Known thrombophilia 4 3 1 0
Previous anticoagulation 16 10 6 0
Concomitant pulmonary embolismg 2 2  
Abbreviations: PTS, postthrombotic syndrome; VTE, venous thromboembolism.
aContinuous data are presented as the means ± standard deviation; categorical data are given as the counts.
bLiver insufficiency defined as ASAT/ALAT (aspartate aminitransferase / alanine aminotransferase) >100.
cDelivery within the previous 6 weeks.
dDefined as contraception, tamoxifen, or substitute.
eWithin the previous month.
fWithin the previous 3 months.
gBoth low-risk pulmonary embolism.
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patency referred to primary treatment success without either 
thrombosis of the treated segment or reintervention. 
Secondary patency primary was treatment success without 
permanent loss of flow in the treated segment irrespective 
of any interval therapies. Primary sustained clinical success 
was defined as the absence of PTS (Villalta score 0–4 
points) without the need for repeated intervention assessed 
at the latest follow-up visit.
Restenosis in the treated venous segment was defined by 
ultrasound as a luminal obstruction >50% of the venous 
cross-sectional area in B-mode or deterioration of the 
Doppler flow pattern from the first postinterventional day 
to the follow-up ultrasound study, including an increase of 
antegrade blood flow velocity to >1 m/s or absent respira-
tory modulation of flow at follow-up if respiratory modula-
tion was present 1 day after stent placement. Restenosis 
occurring in the first 30 days was defined as early onset.
Statistical Analyses
Data were presented as means ± standard deviations or 
absolute numbers for continuous and categorical variables, 
respectively. Categorical data were analyzed using the chi-
square test. Means were compared using a 2-sided paired 
Student t test. Kaplan-Meier survival analysis was used to 
estimate patency rates, which are reported with the 95% 
confidence interval (CI). A p<0.05 indicated statistical sig-
nificance. All statistical analyses were performed using 
STATA statistical software (version 13.0; StataCorp LP, 
College Station, TX, USA).
Results
Mean time between the most recent DVT and intervention 
was 7±14 days in patients with acute DVT and 10±14 years 
in patients with PTS. Ultrasound-assisted thrombolysis was 
performed in 9 patients and pharmacomechanical throm-
bolysis in 1. Among the 10 patients with DVT, complete 
thrombolysis success was achieved in 7; 3 patients had 
>50% of thrombus removed. One acute DVT patient suf-
fered a retroperitoneal hematoma after ultrasound-assisted 
thrombolysis, requiring surgical evacuation.
With the exception of 1 patient, all sinus-Obliquus stents 
were implanted in the left CIV. Twelve patients received 1 
stent only and 12 patients received a distal stent extension 
with a second or third stent. Diameters of the sinus-Obliquus 
stents were 14 mm in 16 patients and 16 mm in 8; stent 
lengths ranged from 80 to 150 mm. Primary treatment suc-
cess was achieved in all 24 patients.
Overall, 17 patients were treated with rivaroxaban (15 
mg twice daily for 3 weeks followed by 20 mg/d) and 6 
received low-molecular-weight heparin as a bridge to vita-
min K antagonist for the initial 3 months postintervention. 
Anticoagulation therapy was stopped at 3 months in 1 
patient with acute DVT and after 6 months in 3 patients (2 
with acute DVT and 1 with PTS). The other patients had 
ongoing anticoagulation therapy.
Follow-up
Mean follow-up was 10±3 months (range 6–18). The pri-
mary patency rate was 92% (95% CI 71% to 98%) at 6 
months and 83% (95% CI 54% to 95%) at 10 months 
(Figure 3). Two patients had minor bleeding during follow-
up (1 patient had mild popliteal hematoma at the puncture 
site and 1 patient had hypermenorrhea).
Three patients had symptomatic stent thrombosis (1 
early and 1 late) or in-stent restenosis. The patient with 
early stent thrombosis had a stent extension below the 
inguinal ligament during the index intervention. The patient 
with late stent thrombosis had recurrent VTE (low-risk pul-
monary embolism) occurring concomitantly at the time of 
Figure 1. Photograph of the sinus-Obliquus stent (courtesy 
of Optimed). *The proximal section of the stent provides high 
radial force at the site of common iliac vein compression, 
enabled by a closed-cell design. The proximal tip of the stent 
has an oblique (35°) design to protect the contralateral iliac 
vein inflow. The proximal tip of the stent contains 4 radiopaque 
markers for correct positioning of the stent (see Figure 2). 
**Owing to its open-cell design, the distal segment of the stent 
provides high flexibility and less radial force to accommodate the 
curved anatomy of the iliac veins during hip flexion.
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stent occlusion. All 3 patients had successful recanalization 
(secondary patency 100%).
The patient with early stent thrombosis underwent suc-
cessful ultrasound-assisted thrombolysis and distal stent 
extension into the deep femoral vein; at the time of stent 
thrombosis, this patient was not on therapeutic anticoagu-
lation. The patient with late stent thrombosis was on 
therapeutic anticoagulation with a vitamin K antagonist; he 
had pharmacomechanical thrombolysis with stent-in-stent 
placement in the CIV. The patient with symptomatic in-
stent restenosis required distal stent extension into the deep 
femoral vein after 4 months. One patient had asymptomatic 
in-stent obstruction <50% by ultrasound and was treated 
conservatively. There were no cases of symptomatic stent 
Figure 2. Digital subtraction venograms from a patient with acute iliofemoral thrombosis. (A) After catheter-directed thrombolysis, 
thrombosis in the external iliac vein is resolved; note the stenosis of the left common iliac vein (typical May-Thurner compression, 
arrows). (B) Balloon angioplasty for predilation of the left common iliac vein using a 14-mm high-pressure balloon catheter. (C) 
Radiograph showing the initial deployment phase of the closed-cell segment of the sinus-Obliquus stent (14×100 mm) at the origin 
of the left common iliac vein. (D) Final venogram of the postdilated sinus-Obliquus stent in the left common and external iliac veins. 
Note that the proximal segment of the stent does not reach the contralateral wall of the inferior vena cava and that the short end of 
the oblique segment was placed ~5 mm inside the inferior vena cava adjacent to the iliac vein confluence.
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compression or contralateral iliac vein thrombosis during 
follow-up.
According to the Bozkaya score,11 all patients had subjec-
tive clinical improvement at the latest follow-up; 50% 
reported complete resolution of symptoms. In patients with 
acute DVT, all patients were free from the PTS at the latest 
follow-up (6 patients had 0 points, 2 patients had 1 point, and 
2 patients had 3 points). In PTS patients, the mean Villalta 
score was 10±3 at baseline and 4±2 at latest follow-up, result-
ing in a statistically significant mean reduction in the Villalta 
score of 6±6 points (p=0.02). The mean rVCSS decreased by 
3±1 points (baseline 5.0±3.9 points; p=0.05). At the latest 
follow-up, 6 of 10 PTS patients had a Villalta score <4, clas-
sifying them as free from PTS after intervention.
Discussion
The sinus-Obliquus stent was designed to accommodate the 
specific needs for treatment of CIV compression. The 
hybrid design with proximal closed-cell and distal open-cell 
segments was chosen to provide maximum radial force at 
the compression site and maximum flexibility in the non-
compressed curved iliac veins. The oblique end of the 
closed-cell section was designed for precise placement at 
the origin of the iliocaval bifurcation without the need to 
place the stent too far into the IVC, thereby reducing the 
risk of jailing the contralateral CIV.
Overall, our findings are consistent with prior studies of 
other venous stents, with good patency, few complications, 
and no mortality.16 A number of dedicated venous stents 
have been investigated, for example, the Vici (VENITI Inc, 
St Louis, MO, USA), Zilver Vena (Cook, Bloomington, IN, 
USA), and the sinus-Venous (Optimed). O’Sullivan et al29 
reported a short-term patency rate of 85% for the Zilver 
Vena stent in patients with acute DVT and malignant venous 
obstructions. Another study investigating the sinus-Venous 
stent in PTS patients reported a patency rate of 99% at 3 
months and 92% at 12 months, resulting in an improvement 
in PTS as reflected by a significant decrease in the VCSS 
and Villalta scores.18
In this study, no differences were found in terms of 
patency rates between thrombotic and nonthrombotic dis-
ease. In contrast, prior evidence suggests that outcomes 
may differ. Recent studies demonstrated that primary 
patency rates were lower for patients with PTS compared 
to patients with nonthrombotic iliac vein stenosis.18,30,31 A 
possible explanation suggested by the authors might be 
that the compromised venous inflow from the femoral 
veins due to postthrombotic lesions may result in higher 
reocclusion rates. Accordingly, our PTS patients were 
treated with an aggressive strategy that called for distal 
stent extension to achieve optimal inflow. In patients with 
iliac vein stenting after catheter-directed thrombolysis, our 
results are similar to others,23 with excellent patency up to 
1 year.
Limitations
This study was limited by the small study population and 
short follow-up. The exact rate of asymptomatic stent com-
pression/restenosis could not be determined because ultra-
sound surveillance may have missed it in patients with 
poor-quality ultrasound images of the iliac veins. However, 
it is unlikely that severe asymptomatic forms were missed 
if the Doppler signal in the common femoral vein remained 
unchanged from the day of intervention to follow-up. Also, 
asymptomatic stent fractures could not be identified 
because routine radiographic examinations were not per-
formed during follow-up. However, it is unlikely that stent 
fractures leading to severe asymptomatic restenosis were 
missed.
Moreover, our population treated with sinus-Obliquus 
stents mainly consisted of young, healthy female patients. If 
treatment with sinus-Obliquus stents becomes a broadly 
accepted therapy, venous stenting has to be studied in mul-
timorbid and elderly patients as well. However, the origi-
nality of our study lies in the fact that acute thrombotic, 
postthrombotic, and nonthrombotic iliac vein compression 
syndromes were investigated.
Conclusion
Short-term patency and clinical outcomes in patients with 
CIV compression treated with the sinus-Obliquus stent 
were excellent. Further studies need to investigate the 
Figure 3. Kaplan-Meier estimates of the primary patency 
rates for 24 patients treated with the sinus-Obliquus stent. The 
standard error is 6% at 10 months.
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efficacy and safety of sinus-Obliquus stenting in a long-
term perspective.
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